ArticleEuropean journal of nuclear medicine and molecular imaging2023
A prognostication system based on clinical parameters and [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- The [European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Tumor lesion detection in patients with cervical cancer by indocyanine green near-infrared imaging.European journal of nuclear medicine and molecular imaging · 2023Trial
- Baseline [European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic significance of FDG-PET/CT based radiomics analysis in newly-diagnosed multiple myeloma: a comparative study with clinical assessment.Frontiers in oncology · 2025Article
- CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.American journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [EJNMMI research · 2024Article
- ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.European journal of nuclear medicine and molecular imaging · 2024Article
- Melanin-targeted [European journal of nuclear medicine and molecular imaging · 2023Article
- Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeThis study aimed to assess prognosis of patients with newly diagnosed multiple myeloma (NDMM) by combining [
methodsClinical data and PET/CT parameters of 133 NDMM patients were retrospectively analyzed for associations between clinical indices and PET/CT parameters. Independent predictors of progression-free survival (PFS) and overall survival (OS) were determined. A new prognostic prediction system (NPPS) was constructed based on our findings. Prediction effectiveness was compared among the NPPS, International Staging System (ISS), Revised ISS (R-ISS), and R2-ISS.
resultsPrevalence of elevated β2-microglobulin, serum creatinine (sCr), serum calcium (sCa), and C-reactive protein concentrations was higher in patients with higher SUVmax (≥ 5.3). Prevalence of elevated sCa, sCr, and extramedullary disease (EMD) was higher in patients with a higher number of focal lesions (≥ 10). SUVmax, serum free-light chain (sFLC) ratio, and EMD were independent predictors of PFS and OS. The NPPS used SUVmax, sFLC ratio, and EMD could effectively predict OS and was more effective at prognostication than the ISS, R-ISS, and R2-ISS.
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.